Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

ands)

201120102010Total cash and marketable securities

$
94,555$
98,037$
202,424(1) Unaudited

(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses.OPERATIONAL HIGHLIGHTS   First quarter 2011 sales of Fanapt® were reported by Novartis to be $9.0 million.  Fanapt® prescriptions, as reported by IMS, reached 25,000 in the first quarter of 2011.

Novartis initiated a clinical study for the once a month injectable depot formulation of Fanapt® in April 2011.  This is a Phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt® in patients with schizophrenia.  A long-acting injectable formulation could offer a potential new option for patients with schizophrenia who might benefit from less frequent dosing compared to an oral medication.

Vanda expects to file for European regulatory approval of oral Fanapt® in the second half of 2011.  This continues the effort to expand the availability of Fanapt® to markets outside the U.S. and Canada.  

On March 31, 2011, Vanda announced plans to evaluate tasimelteon in Major Depressive Disorder.   There is considerable evidence that suggests circadian rhythm disturbances are important in the pathophysiology of mood disorders.  Treatment with tasimelteon would represent a novel and differentiated approach to assisting the millions of patients who suffer from the symptoms of major depression.  A Phase IIb/III clinical trial will examine safety and efficacy of tasimelteon versus placebo and is expected to begin during the second half of 2011.  The study will include an 8-week treatment period and an optional open-label extension.

Enrollment is ongoing in tasimelteon studies VP-VEC-162-3201 (efficacy) and VP-VEC-162-3202 (safety) in the treatment of N24HSWD in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.20 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... candidate, PPL-003, to an Investigational New Drug (IND) application ... uveitis.  PPL recently completed a study in a rat ... achieved highly significant efficacy and a more rapid onset ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... successful food and beverage processors, equipment manufacturers and leaders in the field of ... industrial weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... The state will give $250,000 in tax credits to C3 ... an 18,000-square-foot facility in Appleton's Northeast Business Park. , ,According ... create 28 jobs in the area. The credits are part ... aside $5 million in tax credits for each of eight ...
... up with UW-Eau Claire, UW-Stout and several other tech ... in the state. , ,Nanotechnology deals with particles one ... physical properties of matter begin to give way to ... understand. The potential of arranging nanoparticles, which scientists long ...
... the University of Wisconsin-Madison are taking another look at some ... That's what scientists call the way sounds change as you ... example, a jackhammer or a siren will sound higher pitched ... ,But there's an inverse Doppler effect, too, predicted ...
Cached Biology Technology:Chippewa Valley Technical College helps pioneer nanotech program, incubator 2Chippewa Valley Technical College helps pioneer nanotech program, incubator 3Chippewa Valley Technical College helps pioneer nanotech program, incubator 4
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... when the Food and Drug Administration is reconsidering the ... study offers further evidence to support a University of ... treatment may be in order. Richard ... Houston College of Pharmacy (UHCOP), has been investigating whether ...
... Ill. -- Most people know that too much sodium from ... that people trying to lower their blood pressure should also ... to sodium. Researchers found that the ratio of sodium-to-potassium ... disease than sodium or potassium alone. "There isn,t ...
... the first clinical evidence that gene therapy reduces symptoms ... this promising treatment which has endured a sometimes turbulent ... Human Gene Therapy the findings stem from ... conducted in Germany and led by an investigator at ...
Cached Biology News:New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4Cutting salt isn't the only way to reduce blood pressure 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: